and 3-numerous confluent changes subcategorized into: (a) the hemorrhagic zone, (b) edema, (c) the loss of neurons, (d) vacuoles, and (e) the loss of spinal column tracts [3]
Unlike older peptides, it does this without raising stress hormones like cortisol or prolactin
Over time, obese patients lose roughly 12% of their body weight on Wegovy (semaglutide) and about 18% on Zepbound (tirzepatide, which targets GLP-1 and another gut hormone, GIP.) Diana Thiara, MD, medical director of the UCSF Weight Management Program, says the results can be amazing and life-changing for people with obesity, a condition linked to a host of health risks
By targeting both metabolic and neurodegenerative pathways, GLP-1 receptor agonists represent a multifaceted approach to PD treatment, offering hope for better disease management and improved patient outcomes